Ecuador Says Snowden Seeks Asylum (WSJ)

Share With Friends: | | Politics - Top Stories News, RSS and RSS Feed via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/314696430?client_source=feed&format=rss

Marc Maron amanda knox Carolyn Moos Danny Brown The Following amy schumer amy schumer

Emergency communications demonstration today, Sunday - The St ...

The Ham Radio Operators of the Flagler Emergency Communications Association will join with tens of thousands of other amateur radio operators showing their emergency communications skills for 24 hours beginning at 2 p.m. Saturday.

Working in the training room of the headquarters of the Flagler Beach Fire Rescue Department at 320 South Flagler Ave., groups of local hams will be using voice, Morse Code, computer and even satellites in orbit to simulate emergency conditions that might face local communities.

The public is welcome to stop by and participate in this drill, observe, operate specialized equipment and chat with local hams to learn more about the Amateur Radio Service created under Federal Regulations Title 47 and the regulated by the Federal Communications Commission.

There is no charge to visit the operations of the Flagler Emergency Communications Association and no advance arrangements are necessary.

All are welcome.

This annual event, called ?Field Day,? is the climax of the week long ?Amateur Radio Week? sponsored by the American Radio Relay League, the national association for Amateur Radio.

Source: http://staugustine.com/news/local-news/2013-06-21/emergency-communications-demonstration-today-sunday

james jones james jones black forest aladdin ufc 144 fight card ufc 144 results acura nsx

New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea

Public release date: 22-Jun-2013
[ | E-mail | Share ]

Contact: Pam Eisele
908-423-5042

Kim Hamilton
908-423-6831
908-391-0131

Carol Ferguson
908-423-4465

Merck

WHITEHOUSE STATION, N.J., June 22, 2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions.

"Chronic renal disease is, unfortunately, an increasingly common problem in patients with type 2 diabetesand one which can complicate physicians' management of their patients' blood sugar control," said Peter Stein, vice president of Clinical Research for diabetes and endocrinology, Merck Research Laboratories. "Treatments which can help patients with diabetes and renal insufficiency get to improved glycemic control, without increasing the risk of hypoglycemia, may be very useful."

Patients taking JANUVIA 100 mg once-daily achieved similar blood sugar reductions (-0.62 LS mean A1Cⁱ reduction from a baseline of 7.6%) as patients taking a sulfonylurea (-0.68 LS mean A1C reduction from a baseline of 7.6%).

Of the patients taking JANUVIA (sitagliptin), 6.8 percent experienced one or more episodes of symptomatic hypoglycemia, compared to 26.2 percent of patients taking a sulfonylurea (p

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.

Design of Post-hoc Analysis

This post-hoc analysis pooled data from three randomized, double-blind studies conducted over 25-30 weeks that included 1,180 patients with type 2 diabetes and mild renal insufficiencyⁱⁱ. The analysis compared the effects of JANUVIA 100 mg (n=584) once daily to a sulfonylurea, either glipizide or glimepiride (n=596) in titrated doses, on change from baseline in A1C, fasting plasma glucose, body weight, and the incidence of symptomatic hypoglycemia.

Selected Important Risk Information About JANUVIA (sitagliptin) 50 mg, 100 mg tablets

JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA (sitagliptin), observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis. Caution should be used to ensure that the correct dose of JANUVIA is prescribed.

There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal insufficiency, some of whom were prescribed inappropriate doses of sitagliptin.

When JANUVIA was used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.

The incidence (and rate) of hypoglycemia based on all reports of symptomatic hypoglycemia were: 12.2 percent (0.59 episodes per patient-year) for JANUVIA 100 mg in combination with glimepiride (with or without metformin), 1.8 percent (0.24 episodes per patient-year) for placebo in combination with glimepiride (with or without metformin), 15.5 percent (1.06 episodes per patient-year) for JANUVIA 100 mg in combination with insulin (with or without metformin), and 7.8 percent(0.51 episodes per patient-year) for placebo in combination with insulin (with or without metformin).

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.

Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA (sitagliptin).

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in greater than or equal to 5 percent of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

###

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (http://www.sec.gov).

ⁱ A1C is a measure of a person's average blood glucose over a two- to three-month period.

ⁱⁱ The estimated Glomerular Filtration Rate (eGFR) is an overall index of kidney function. The National Kidney Foundation's criteria for mild renal insufficiency is eGFR = 60 to 89 mL/min/1.73 m2.

Prescribing Information and Medication Guide for JANUVIA (sitagliptin) are available at http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf and http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_mg.pdf.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 22-Jun-2013
[ | E-mail | Share ]

Contact: Pam Eisele
908-423-5042

Kim Hamilton
908-423-6831
908-391-0131

Carol Ferguson
908-423-4465

Merck

WHITEHOUSE STATION, N.J., June 22, 2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions.

"Chronic renal disease is, unfortunately, an increasingly common problem in patients with type 2 diabetesand one which can complicate physicians' management of their patients' blood sugar control," said Peter Stein, vice president of Clinical Research for diabetes and endocrinology, Merck Research Laboratories. "Treatments which can help patients with diabetes and renal insufficiency get to improved glycemic control, without increasing the risk of hypoglycemia, may be very useful."

Patients taking JANUVIA 100 mg once-daily achieved similar blood sugar reductions (-0.62 LS mean A1Cⁱ reduction from a baseline of 7.6%) as patients taking a sulfonylurea (-0.68 LS mean A1C reduction from a baseline of 7.6%).

Of the patients taking JANUVIA (sitagliptin), 6.8 percent experienced one or more episodes of symptomatic hypoglycemia, compared to 26.2 percent of patients taking a sulfonylurea (p

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.

Design of Post-hoc Analysis

This post-hoc analysis pooled data from three randomized, double-blind studies conducted over 25-30 weeks that included 1,180 patients with type 2 diabetes and mild renal insufficiencyⁱⁱ. The analysis compared the effects of JANUVIA 100 mg (n=584) once daily to a sulfonylurea, either glipizide or glimepiride (n=596) in titrated doses, on change from baseline in A1C, fasting plasma glucose, body weight, and the incidence of symptomatic hypoglycemia.

Selected Important Risk Information About JANUVIA (sitagliptin) 50 mg, 100 mg tablets

JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA (sitagliptin), observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis. Caution should be used to ensure that the correct dose of JANUVIA is prescribed.

There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal insufficiency, some of whom were prescribed inappropriate doses of sitagliptin.

When JANUVIA was used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.

The incidence (and rate) of hypoglycemia based on all reports of symptomatic hypoglycemia were: 12.2 percent (0.59 episodes per patient-year) for JANUVIA 100 mg in combination with glimepiride (with or without metformin), 1.8 percent (0.24 episodes per patient-year) for placebo in combination with glimepiride (with or without metformin), 15.5 percent (1.06 episodes per patient-year) for JANUVIA 100 mg in combination with insulin (with or without metformin), and 7.8 percent(0.51 episodes per patient-year) for placebo in combination with insulin (with or without metformin).

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.

Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA (sitagliptin).

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in greater than or equal to 5 percent of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

###

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (http://www.sec.gov).

ⁱ A1C is a measure of a person's average blood glucose over a two- to three-month period.

ⁱⁱ The estimated Glomerular Filtration Rate (eGFR) is an overall index of kidney function. The National Kidney Foundation's criteria for mild renal insufficiency is eGFR = 60 to 89 mL/min/1.73 m2.

Prescribing Information and Medication Guide for JANUVIA (sitagliptin) are available at http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf and http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_mg.pdf.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2013-06/gg-nas062113.php

adriana lima victoria secret fashion show SEC Championship Rick Majerus Cotto vs Trout Robin Givens Gus Malzahn

lern2play Resources and Information. This website is for sale!

By using our site, you consent to this privacy policy: This website allows third-party advertising companies for the purpose of reporting website traffic, statistics, advertisements, "click-throughs" and/or other activities to use Cookies and /or Web Beacons and other monitoring technologies to serve ads and to compile anonymous statistics about you when you visit this website. Cookies are small text files stored on your local internet browser cache. A Web Beacon is an often-transparent graphic image, usually no larger than 1 pixel x 1 pixel that is placed on a Web site. Both are created for the main purpose of helping your browser process the special features of websites that use Cookies or Web Beacons. The gathered information about your visits to this and other websites are used by these third party companies in order to provide advertisements about goods and services of interest to you. The information do not include any personal data like your name, address, email address, or telephone number. If you would like more information about this practice and to know your choices about not having this information used by these companies, click here.

Source: http://feeds.feedburner.com/lern2play

pacquiao Jim DeMint Dave Brubeck frankie muniz katt williams greg mcelroy bob costas

More U.S. senators concerned by Shuanghui-Smithfield deal

WASHINGTON (Reuters) - More U.S. senators on Friday raised concerns about a Chinese company's plan to buy U.S. pork company Smithfield Foods Inc , particularly in light of restrictions that China continues to place on imports of U.S. meat.

"This review must be thorough and take into account the full range of national security interests," the top Democrat and Republican on the Senate Finance Committee said in a letter to U.S. Treasury Secretary Jack Lew and U.S. Trade Representative Michael Froman.

"In particular, we urge that due consideration be given to the impact of the transaction on food safety in the United States," added Senators Max Baucus, a Montana Democrat and the committee's chairman, and Orrin Hatch, a Utah Republican.

That echoed a demand made on Thursday by 15 of the 20 members of the Senate Agriculture Committee.

Chinese meat company Shuanghui International hopes to buy Smithfield, the world's largest pork producer and processor, for $4.7 billion in what would be the biggest takeover of a U.S. company by a Chinese firm.

The companies, out of what lawyers said was "an abundance of caution," filed the proposed deal with the Committee on Foreign Investment in the United States (CFIUS) which reviews foreign investment for any potential threat to national security.

Many CFIUS experts believe it is unlikely the Obama administration will decide that Chinese investment in the U.S. food sector is a national security threat.

"I think the Chinese will bring home the bacon," said Timothy Keeler, a former U.S. Treasury and trade official who now advises companies with deals that go before CFIUS.

In a statement on Thursday, Smithfield said it welcomed a full review of the deal and would continue to cooperate with the administration and Congress in that effort.

"We believe the proposed combination does not present any national security concerns, is good for U.S. farmers and agriculture and will advance U.S.-China relations," a spokeswoman for Smithfield said.

Baucus and Hatch said the proposed sale threw a spotlight on longtime Chinese restrictions on U.S. meat, and urged the Obama administration to aggressively push back on those measures.

"The purchase of Smithfield - the largest pork producer in the world - is difficult to square with China's restrictive policies that effectively ban U.S. pork," the senators said.

China currently bans imports of pork containing any residue of ractopamine, a feed additive used widely in the United States with backing from the Codex Alimentarius, the international food safety standards body.

It also blocks imports of almost all U.S. beef because of mad cow disease concerns, despite a finding by the World Animal Health Organization that U.S. beef is safe.

"As a result, while Chinese meat producers are free to bid on U.S. companies accounting for a significant share of U.S. pork production, our producers remain shut out of the important Chinese market," the senators said.

(Reporting by Doug Palmer; Editing by Eric Walsh)

Source: http://news.yahoo.com/more-u-senators-concerned-shuanghui-smithfield-deal-214716325.html

David Rakoff Bourne Legacy London 2012 Soccer Olympics closing ceremony PGA Championship 2012 John Witherspoon george michael

Why Your DVR Hates the Last Few Seconds of Shows So Much

There's nothing quite like missing the very last seconds of that show you so painstakingly DVRed. Especially if that show is a live sporting event, and you explicitly told the damned box to keep going for an hour or two afterwards. It shouldn't have to be that way, though. And as Slate explains, there's a better world of perfect recording just across the pond.

The problem isn't quite that your DVR is stupid, but rather that it's being fed bad information. Standard American DVRs only know what's on by looking at on-screen programming guides, which are put out and updated by some third-party, not the people who are actually running the shows. And when those guides switch out just a second too early, you're screwed. It's a wildy inaccurate system.

It's different in Europe. Slate explains:

[Broadcasters supply] what?s called ?present and following? information?that is, the identity of the program that?s airing right now and the one that?s scheduled to air next. Even if a program (like, say, a sporting event) is supposed to end at 10:30 p.m., the broadcaster will not change that present and following data until the game is actually over.

And why don't we have that here? It's less a technical reason and just that no one is really asking for it. Come on, guys. You can read more about the ins and outs of the problem over at Slate. And sure, it'd be nice to just go all digital, all on-demand streams. But in the meantime, this is a good thing to fix. [Slate]

Image by Vasaleks/Shutterstock

Source: http://gizmodo.com/why-your-dvr-hates-the-last-few-seconds-of-shows-so-muc-541414934

bank of america online banking Adairsville Ga ashley judd Alois Bell Donna Savattere deer antler spray Jason London

Is the drop in financial markets an overreaction?

Specialist John Urbanowicz works on the floor of the New York Stock Exchange, Thursday, June 20, 2013. Financial markets are sliding after the Federal Reserve said it could end its huge bond-buying program by the middle of next year. (AP Photo/Richard Drew)

Specialist John Urbanowicz works on the floor of the New York Stock Exchange, Thursday, June 20, 2013. Financial markets are sliding after the Federal Reserve said it could end its huge bond-buying program by the middle of next year. (AP Photo/Richard Drew)

Specialist Mario Picone works on the floor of the New York Stock Exchange, Thursday, June 20, 2013. Financial markets are sliding after the Federal Reserve said it could end its huge bond-buying program by the middle of next year. (AP Photo/Richard Drew)

Specialist John O'Hara works at his post on the floor of the New York Stock Exchange, Thursday, June 20, 2013. Financial markets are sliding after the Federal Reserve said it could end its huge bond-buying program by the middle of next year. (AP Photo/Richard Drew)

Trader Justin Flinn works in a booth on the floor of the New York Stock Exchange, Thursday, June 20, 2013. Financial markets are sliding after the Federal Reserve said it could end its huge bond-buying program by the middle of next year. (AP Photo/Richard Drew)

NEW YORK (AP) ? Stunned investors are now wondering whether the markets' big sell-off was an overreaction or a sign of more volatility to come.

Global financial markets plunged Thursday after the Federal Reserve roiled Wall Street by saying it could reduce its aggressive economic stimulus program later this year. Concerns about China's economy heightened worries.

The global selling spree began in Asia and quickly spread to Europe and then the U.S., where the Dow Jones industrial average fell 353 points, wiping out six weeks of gains.

But the damage wasn't just in stocks. Bond prices fell, and the yield on the benchmark 10-year Treasury note rose to 2.42 percent, its highest level since August 2011, although still low by historical standards. Oil and gold also slid.

"People are worried about higher interest rates," said Robert Pavlik, chief market strategist at Banyan Partners. "Higher rates have the ability to cut across all sectors of the economy."

The losses extended into Asia early Friday. Hong Kong's Hang Seng tumbled 1.5 percent, while South Korea's Kospi declined 2 percent. Japan's Nikkei 225 index, the regional heavyweight, fell marginally.

So what next? Traders and investors are looking for a new equilibrium after a period of ultra-low rates, due to the Fed's bond-buying, which helped spawn one of the great bull markets of all time.

It doesn't mean the stock run-up is over. After all, the S&P 500 is still up 11.4 percent for the year and 135 percent since a recession low in March 2009. But it may suggest the start of a new phase in which the fortunes of the stock market are tied more closely to the fundamentals of the economy.

And that might not be a bad thing. The reason the Fed is pulling back on the bond-buying is because its forecast for the economy is getting brighter.

The job market is improving, corporations are making record profits and the housing market is recovering.

"People are overreacting a little bit," said Gene Goldman, head of research at Cetera Financial Group. "It goes back to the fundamentals, the economy is improving."

The Dow's drop Thursday ? which knocked the average down 2.3 percent to 14,758.32 ? was its biggest since November 2011. It comes just three weeks after the blue-chip index reached an all-time high of 15,409. The index has lost 560 points in the past two days, wiping out its gains from May and June

The Standard & Poor's 500 lost 40.74 points, or 2.5 percent, to 1,588.19. It also reached a record high last month, peaking at 1,669. The Nasdaq composite fell 78.57 points, or 2.3 percent, to 3,364.63.

Small-company stocks fell more than the rest of the market Thursday, a sign that investors are aggressively reducing risk. The Russell 2000 index, which includes such stocks, slumped 25.98 points, or 2.6 percent, to 960.52. The index closed at a record high of 999.99 points Tuesday.

The yield on the 10-year Treasury note rose to 2.42 percent, from 2.35 percent Wednesday. The yield, which rises as the price of the note falls, surged 0.16 percentage point Wednesday after the Fed's comments. As recently as May 3, it was 1.63 percent.

A Fed policy statement and comments from Chairman Ben Bernanke started the selling in stocks and bonds Wednesday.

Bernanke said that the Fed expects to scale back its massive bond-buying program later this year and end it entirely by mid-2014 if the economy continues to improve.

The bank has been buying $85 billion a month in Treasury and mortgage bonds, a program that has made borrowing cheap for consumers and business. It has also helped boost the stock market.

Alec Young, a global equity strategist at S&P Capital IQ, said investors weren't expecting Bernanke to say the program could end so quickly, and are adjusting their portfolios in anticipation of higher U.S. interest rates.

"What we're seeing is a pretty significant sea-change in investor strategy," Young said

For much of the year, the stock market rose with barely an interruption. The S&P 500 climbed for seven months straight from November 2012 through May. Investors, fearful of missing out on the rally, pounced on any dips and pushed markets to record highs. On Thursday, those opportunistic buyers were absent. Nobody wanted to stand in the way of the market's slide.

As investors sold stocks, they likely put the proceeds in cash "for fear the deterioration will continue," said Quincy Krosby, a market strategist at Prudential Financial.

The sharp increase in bond yields prompted investors to sell homebuilders, whose business could be hurt if the pace of home buying slows down. Those stocks fell Thursday even though the National Association of Realtors said U.S. sales of previously occupied homes last month topped 5 million at an annual rate for the first time in 3 ? years.

PulteGroup plunged $1.89, or 9.1 percent, to $18.87. D.R. Horton fell $2.13, also 9.1 percent, to $21.31.

Markets were also unnerved after manufacturing in China slowed at a faster pace this month as demand weakened. That added to concerns about growth in the world's second-largest economy. A monthly purchasing managers index from HSBC fell to a nine-month low of 48.3 in June. Numbers below 50 indicate a contraction.

A big jump in the overnight lending rate in China also unsettled investors, said Brad Reynolds, a financial adviser at LJPR. The rate measures how much banks charge each other to borrow short-term money. The People's Bank of China was forced to pump about 50 billion yuan, about $8 billion, into the Chinese financial system to alleviate the squeeze, Bloomberg News reported.

Before trading began Thursday on Wall Street, Japan's Nikkei index lost 1.7 percent. The FTSE 100 index of leading British shares fell 3 percent while Germany's DAX dropped 3.3 percent.

In currency trading, the dollar rose to 97.34 Japanese yen from 96.54 yen. The euro fell against the dollar, to $1.3197 from $1.3274.

Gold plunged, leading a rout in commodity prices. Gold dropped $87.80, or 6.4 percent, to $1,286.20 an ounce. Silver fell $1.80, or 8.3 percent, to $19.823 an ounce. Both are at their lowest since September 2010.

Traders dumped gold and silver as their appeal as insurance against inflation and a weak dollar faded. Both became less of an issue after the Fed said it was contemplating an end to its bond-buying program.

Oil was swept up in the sell-off. Crude oil had its biggest one-day price drop since November. U.S. benchmark oil for July delivery sank $2.84, or 2.9 percent, to finish at $95.40 a barrel in New York. Gasoline futures fell more than 3 percent.

Some investors said the sell-off in stocks may be overdone. The Fed is considering easing back on its stimulus because the economy is improving. The central bank has upgraded its outlook for unemployment and economic growth.

The S&P 500 is still up 11.3 percent, for the year, not far from its full-year increase of 13.4 percent last year.

.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/3d281c11a96b4ad082fe88aa0db04305/Article_2013-06-21-Wall%20Street/id-0de184451d4041709211b38a23ec9431

the curious case of benjamin button secret service prostitute rich ross april 20 secret service prostitution 4 20 sheree whitfield

Apparently Google is internally testing a service called "Google Mine" that lets you index all your

Apparently Google is internally testing a service called "Google Mine" that lets you index all your crap on Google+. Like, the physical items you own. You'll be able to share them on Google+ and set statuses for them like "given away," "gift recieved" or "had in the past." Of course Google would like to know that.

Source: http://gizmodo.com/apparently-google-is-internally-testing-a-service-calle-531459420

2013 lincoln mkz burger king mary j blige google project glass google goggles one tree hill projectglass stock act

News in Brief: Some infertile men have heightened cancer risk

Those who don?t make sperm are more apt to develop malignancy

By Nathan Seppa

Web edition: June 21, 2013

Men who don?t produce sperm face nearly three times the risk of cancer compared with the male population average, researchers report June 20 in Fertility and Sterility.

About 4 million men in the United States are infertile, with a host of causes. Of them, about 600,000 men don?t deliver sperm from the testes to the semen at all.

Michael Eisenberg of Stanford University and his colleagues studied the medical records of Texas men who had visited a male health clinic between 1989 and 2009. The men averaged 36 years old when they were examined. Of 2,238 men found to be infertile, about one-fifth didn?t have any sperm in their semen.

Over an average follow-up time of 6.7 years, 10 of the 451 men who didn?t make sperm developed some kind of cancer, making them 2.9 times as likely as similar-aged men in the general Texas population to be diagnosed with cancer. The reason is unclear, the authors say. Men who were infertile for other reasons didn?t face an increased risk of cancer.?

Source: http://www.sciencenews.org/view/generic/id/351157/title/News_in_Brief_Some_infertile_men_have_heightened_cancer_risk

watergate pregnant man outside lands 2012 lineup beloved ufc results water for elephants old school

Markets roiled by Bernanke's exit strategy

LONDON (AP) ? Financial markets were roiled Thursday by a clear signal from U.S. Federal Reserve Chairman Ben Bernanke that the central bank may be done with its monetary stimulus program by next year. While stocks and commodities took a pounding on the news, the dollar surged.

For nearly five years, the Fed has been pursuing an aggressive monetary policy to shore up the U.S. economy, which was battered by the financial crisis in 2008. Now that the U.S. economy has shown signs of improvement, Bernanke said the Fed is considering when it should start normalizing its policy.

In the latest round of its monetary stimulus program ? known as quantitative easing, or QE ? the Fed has been buying $85 billion worth of financial assets each month to keep long-term interest rates low. This, it hopes, will boost borrowing and spending. After the Fed's decision to keep the policy unchanged, Bernanke confirmed that the central bank's purchases will likely slow down this year and end next year. When the reduction ? so-called tapering ? begins will hinge on the U.S. economic data, though.

That prompted some concern among investors who have grown used to the Fed's active involvement in the financial markets ? the Dow tumbled over 200 points Wednesday while oil and gold prices slid ? even though the remarks signal a healthier U.S. economic outlook. Much of the reason why a number of assets, including stocks around the world, have advanced over the past few years is that the money created by central banks through QE has found itself in financial markets.

"With an unexpectedly upbeat assessment of the U.S.'s economic prospects, an exit path from quantitative easing was duly mapped out," said Mike Ingram, market strategist at BGC Partners. "I was clearly not alone in being caught off guard; markets worldwide have plunged in response. The tide of red now engulfing my screens is indeed impressive in its breadth-if not yet depth. Virtually every financial asset has been sold. Equity, credit, bonds, commodities; all have suffered."

In Europe's stock markets, the FTSE 100 index of leading British shares ended Thursday trading down 2.98 percent at 6,159 while Germany's DAX dropped 3.28 percent to 7,928. The CAC-40 in France was 3.6 percent lower at 3,698.

In the U.S., stocks were down again, with the Dow Jones industrial average 1.2 percent lower at 14,925 and the broader S&P 500 index down 1.37 percent at 1,606.

Earlier, stocks in Asia tanked too, with stocks further negatively impacted by a private survey showing a slowdown in manufacturing in China in June. Among Asia's markets, Tokyo's Nikkei 225 fell 1.7 percent to 13,014.58 while Hong Kong's Hang Seng tumbled 2.9 percent to 20,382.87.

It's not just stocks that have responded to the developments with the Fed. U.S. Treasuries have slid, and the yield on the country's benchmark ten-year bond has risen to 2.4 percent, its highest level since October 2011.

In the currency markets, the dollar has pushed higher as the prospect of new Fed money has diminished in light of Bernanke's statement. The euro was down 0.4 percent at $1.3225 while the dollar rose 1.5 percent to 98.08 yen.

The dollar's surge is having a particular impact on commodities, which are priced in the currency.

The benchmark New York oil price was down $3.18 at $95.29 a barrel, while the gold price slid 5.9 percent, or $81.10, to three-year lows of $1,293 an ounce.

Michael Hewson, senior market analyst at CMC Markets, said gold, for so long a preferred investment for the risk-averse, could fall further now that the $1,300 level has been breached.

"While the timeline for the Fed exit strategy is very much data dependent and based on a whole host of economic indicators between now and next summer, gold prices have slid sharply as the dollar goes sharply bid across the board," said Hewson.

Source: http://news.yahoo.com/markets-roiled-bernankes-exit-strategy-094255558.html

URI Facebook Home Ncaa Basketball Tournament 2013 Robert Ebert chelsea handler hannibal Lena Headey

Best apps every iPhone owner should download right now!

iMore's guide to the best apps available for iPhone. From camera apps to calendar alternatives to cloud storage and more.

Why is it so hard to find great apps? That's the question we asked today on Talk Mobile. One of the reasons is that there are literally hundreds of thousands of apps available in the App Store, even if we just count iPhone apps alone. With so many to choose from, it can be tough to find the absolute best one, not to mention expensive. We're here to help.

While we do tons of app reviews and weekly app picks, over and above all of that there are the apps that we think are simply best in class. These are the ones that we download on our iPhones immediately and use all the time.

These are the best apps for iPhone, as of the summer of 2013.

Best camera app: VSCO Cam

There is no shortage of camera and photo editing apps in the App Store. The best of the best combine both into one and give you the option to share to your social networks of choice, all in one place. That's why we recommend VSCO Cam. Not only does it balance ease of use with features, it's gorgeously designed, wicked fast, and free. From taking photos to giving you access to everything you've snapped with VSCO Cam in one place, it does a great job of balancing the need to create beautiful photos with getting them where they need to be with just a few taps.

• Free - Download Now

Best calendar app: Fantastical

When it comes to calendar apps, Fantastical sets the bar for all the others. Not only is it absolutely gorgeous, but it understands natural language input. Launch Fantastical, tap the dictation button, and say what you'd like it to add. It's even smart enough to switch between calendars by simply adding the calendar name to the end of whatever you'd like to add. It's much quicker than the default calendar but brings all your events over with no setup required. Not to mention, it's beautifully designed.

• $4.99 - Download Now

Best cloud storage app: Dropbox

For many of us, Dropbox is a regular part of our workflow. Whether you use it daily or just a few times a week or month, the iPhone app is a must have. Automatic upload for photos is easy and allows you to save precious storage space on your iPhone. It's also great for the times that you need to upload other kinds of files to Dropbox. It's the number one file sharing service for a reason, and if you've got an iPhone, the Dropbox app is an essential.

• Free - Download Now

Best ebook reader app: iBooks

iBooks is Apple's free ebook and PDF reading app for iPhone. It's a stylish way to read not only books purchased from the iBookstore, but all the free books from the massive Project Gutenberg library as well as any of your own ePub or PDF files. Apple's book catalog isn't as big as Amazon's Kindle library, but the reading experience itself is far superior.

• Free - Download Now

Best educational video app: Khan Archiver

Khan Academy is one of the best products of education and the internet, and with the Khan Archiver app for the iPhone, you have free access videos on topics ranging from kindergarten, advanced science, humanities, history, and more. You can even download the videos to watch offline.

• Free - Download Now

Best alternative email app: Mailbox

If you use Gmail, Mailbox is a great way to clean out your inbox with a quickness. From gesture support to the gorgeous interface, Mailbox is a great alternative to the default Mail app for Gmail users. It works by auto-creating labels and allowing you to sort emails with them. Want to remember to do something later? Just snooze the message for a later time and it'll automagically re-appear at the time you've specified. It also supports push notifications which make it a completely viable alternative if you live and breathe Gmail.

• Free - Download Now

Best launcher app: Launch Center Pro

"Launch actions, not apps" is Launch Center Pro's motto and the app allows you to do just that. From composing an email/message (with or without a default recipient/body), to creating quick dialers, Safari searches and page launches, to a flashlight utility, and the ability to insert a custom URL string that can either launch an app function or a web page, Launch Center lets you do everything you need to do on your iPhone, faster than ever before.

• $2.99 - Download Now

Best navigation app: Google Maps

We are all very familiar with the issues Apple has with their default Maps app. While they continue to improve upon that, Google Maps is still a fan favorite and for good reason. Not only is it a native standalone app now, it also has some of the best maps available. From turn-by-turn to walking directions, Google Maps does it all, with a gorgeous design to boot.

• Free - Download Now

Best password manager app: 1Password

We live in a world where we have passwords for our passwords, 2-step authentication, and more. It's never been more important to have good passwords for all of our accounts without duplicating them. This obviously makes the task of remembering them all more complex and at times, almost impossible. This is where 1Password is essential. Not only can it store all your passwords and allow you to access and sync them across virtually any device you own, it can also help you generate strong ones. If you don't have a password manager, 1Password is what you want.

• $8.99 - Download Now

Best personalized magazine app: Zite

Zite is not only personal to each user, but it grows more personal over time as you use it. The way Zite recommends new content is something none of its competitors can match. Bottom line, Zite is the best social magazine app currently available on the iPhone.

• Free - Download Now

Best podcast app: Instacast 3

We've taken a look at quite a few podcast apps over the years and Instacast is still one of our favorites. From the way it handles podcasts to how it lets you interact with them, it's a great option for hardcore podcast listeners while still being simple enough for users who just don't care for Apple's native Podcasts app.

• $4.99 - Download Now

Best read later app: Pocket

Pocket provides the best design and user experience for the broadest base of users, both on the app and on the website. If you want more than Apple's built in Reading List provides, or you're new to the whole idea of "read later" and time-shifting content, give Pocket a go.

• Free - Download Now

Best RSS app: Reeder

Out of all the RSS apps available in the App Store, Reeder has been a long time favorite here at iMore. Not only will it still be kicking once Google Reader closes its doors for good, it's still one of the absolute best options. From the way it organizes and manages articles to how easy it is to set up and start using, it's a winner. It manages to give you the news you want while getting out of the way leaving you with just your content. And in an RSS app, that's what's important.

• $2.99 - Download Now

Best stocks app: Bloomberg

Bloomberg for iPhone is a great way for casual traders and investors to interact with their stocks and stay up to date with world news. Whether you need to casually monitor stocks on your iPhone or just find the urge to check out financial news, the free Bloomberg app has you covered -- for free!

• Free - Download Now

Best streaming music app: Songza

There's lots of streaming services out there for iPhone but Songza probably takes the cake for most creative way for discovering music. Songza's Music Concierge service can help you find music based on your moods. Are there other robust options out there with more features? Sure. But for a free service with a vast collection and a great interface, you can't go wrong with Songza and for casual listening, it's our favorite.

• Free - Download Now

Best text editor app: Byword

Byword just got even better with the release of Byword 2. With the option for premium subscriptions for publishing straight to Wordpress, Drupal, and other content management systems, Byword is a great way to get your thoughts out. Whether you're a student or a professional writer, Byword gives you the tools you need to manage your writing. With iCloud sync, markdown support, and more, it's a clean, easy to use, and reasonably priced text editor that's the best in its class. If you're looking for a writing suite, look no further than Byword.

• $2.99 - Download Now

Best travel advisory app: TripIt

The free TripIt app for iPhone, when paired with a free TripIt account, becomes your virtual travel assistant. Simply email any flight or hotel confirmations to TripIt and they'll automagically get logged and displayed on your iPhone, along with helpful maps and additional information to make your travel safer and easier.

• Free - Download Now

Best task management app: Omnifocus

It's hard to beat OmniFocus' feature set, which includes Siri integration, location-based reminders, and Forecasts. If price is no object, and you want the most powerful, versatile task management solution for iPhone, with options for syncing with iPad and/or Mac, then you want OmniFocus.

• $19.99 - Download Now

Best Twitter app: Tweetbot

Tweetbot might feel over-designed to some, but it's well-designed. It has a ton of features for power users, including the best push-notification implementation in the business. As far as general purpose Twitter apps go, Tweetbot hits the best balance for the widest range of our readers.

• $2.99 - Download Now

Best VNC app: Screens

With iCloud integration, SSH keys, and a re-designed Screens Connect, Screens 2.0 handles remote computing better and faster than ever before. Screens is also the most iPhone, iPad, and Mac-like remote computing app on the market today, and that makes it the easiest to setup and the most familiar to use.

• $19.99 - Download Now

Best weather app: Yahoo! Weather

Yahoo! Weather was completely revamped recently to feature a gorgeous interface that integrates Flickr photos of the locations you're looking at the weather at. There may be more robust and feature packed weather apps available, but when it comes to design and ease of use, Yahoo! Weather can't be beat. It's no wonder Apple chose to use it natively in iOS 7. If you want the experience now, you can get it by downloading Yahoo! Weather.

• Free - Download Now

Best web browser app: Chrome

If you want a browser that has a better layout than Safari and allows you easy access to bookmarks and other open tabs across all your desktop computers, Chrome is it. There may not be gesture support or a ton of customization options, but it works flawlessly and has a beautiful interface.

• Free - Download Now

Your picks?

These may be our favorites but we know you all have your own too. Think we overlooked something or missed an especially awesome app? Let us know in the comments!

This is your community, so help us make future guides your choice!

Source: http://feedproxy.google.com/~r/TheIphoneBlog/~3/_1A5bW-dadA/story01.htm

Jaromir Jagr Shain Gandee mlb yankees Bb&t Maria Sibylla Merian cory monteith

Protests build in Brazil as discontent spreads

By Todd Benson and Asher Levine

SAO PAULO (Reuters) - Tens of thousands of demonstrators marched through the streets of Brazil's biggest cities on Monday in a growing protest that is tapping into widespread anger at poor public services, police violence and government corruption.

The marches, organized mostly through snowballing social media campaigns, blocked streets and halted traffic in more than a half-dozen cities, including Sao Paulo, Rio de Janeiro, Belo Horizonte and Brasilia, where demonstrators swarmed past the Congress and Presidential Palace.

While peaceful, and unfolding mostly as a festive display of dissent, Monday's demonstrations were the latest in a flurry of protests over the past two weeks that have added to unease over Brazil's sluggish economy, high inflation and a spurt in violent crime.

The marches began this month with a small protest in Sao Paulo against a small increase in bus and subway fares. The demonstrations initially drew the scorn of many middle-class Brazilians after protesters vandalized storefronts, subway stations and buses on one of the city's main avenues.

But the movement quickly gained support and spread to other cities as police used heavy-handed tactics to try to quell the demonstrations. The biggest crackdown happened on Thursday in Sao Paulo when police fired rubber bullets and tear gas in clashes that injured more than 100 people, including 15 journalists, some of whom said they were deliberately targeted.

The protests have gathered pace as Brazil is hosting the soccer Confederation's Cup, a dry run for next year's World Cup. The government hopes these events, along with the 2016 Summer Olympics, will showcase the country as an emerging power on the global stage.

Brazil is also gearing up to welcome more than 2 million visitors in July as Pope Francis makes his first foreign trip for a gathering of Catholic youth in Rio.

Contrasting the billions in public money spent on new stadiums with the shoddy state of Brazil's public services, protesters are using the Confederation's Cup as a counterpoint to amplify their concerns. The tournament got off to shaky start this weekend when police clashed with demonstrators outside stadiums at the opening matches in Brasilia and Rio.

"We shouldn't be spending public money on stadiums," said one protester in Sao Paulo who identified herself as Camila, a 32-year-old travel agent. "We don't want the Cup. We want education, hospitals, a better life for our children."

Other common grievances at Monday's marches included political corruption and the inadequate and overcrowded public transportation networks that Brazilians cope with daily.

POLICE ORDERED TO USE RESTRAINT

The harsh police reaction to last week's protests touched a nerve in Brazil, which endured two decades of political repression under a military dictatorship that ended in 1985. It has also added to doubts about whether Brazil's police forces would be ready for next year's World Cup.

Jose Vicente da Silva, a security consultant and retired police colonel, said training for the big events has focused too much on elite forces instead of the rank-and-file officers who must face the public.

The clashes, he said, "suggest that the everyday policeman in Sao Paulo has barely trained at all" in how to handle a demonstration.

The uproar following last week's crackdown prompted Sao Paulo state Governor Geraldo Alckmin, who initially described the protesters as "troublemakers" and "vandals," to order police to allow Monday's march to proceed and not to use rubber bullets.

The protests are shaping up as a major political challenge for Alckmin, a former presidential candidate, and Sao Paulo's new mayor, Fernando Haddad, a rising star in the left-leaning Workers' Party that has governed Brazil for the past decade. Both have so far insisted that the bus fare hike that sparked the protests is non-negotiable.

Brazilian President Dilma Rousseff, who has enjoyed high approval ratings since taking office in 2011, only recently began to slip in opinion polls. Although the protests have gained traction, they do not appear to reflect any broad-based collapse in her support, but Rousseff was booed at Saturday's Confederations Cup opener.

Still, the resonance of the demonstrations underscores what economists say will be a challenge for Rousseff and other Brazilian leaders in the years ahead: providing public services to meet the demands of the growing middle class.

"Voters are likely to be increasingly disgruntled on a range of public services in a lower growth environment," Christopher Garman, a political analyst at the Eurasia Group, wrote in a report.

(Additional reporting by Esteban Israel and Brian Winter.; Editing by Paulo Prada and Christopher Wilson)

Source: http://news.yahoo.com/protests-build-brazil-discontent-spreads-224858600.html

cleveland plain dealer john scott barry sanders barry sanders jimmie johnson juan pablo montoya crash chardon high school shooting

10 Things to Know for Tuesday

Your daily look at late-breaking news, upcoming events and the stories that will be talked about Tuesday:

1. SUPREME COURT THROWS UP AN OBSTACLE

Monday's ruling will make it harder for states seeking to bar people who are in the U.S. illegally from voting.

2. PUTIN SAYS HE WON'T BUDGE

At the G-8 summit, Russia's leader rejects calls from the West to halt his support of Syria's Assad.

3. TAKING STOCK OF IRAN'S NEW LEADER

Hasan Rowhani may be hailed as a force for change, but he also appears to know he'll be able to push his views only so far.

4. PENTAGON OUTLINES PLAN TO EXPAND WOMEN'S COMBAT ROLES

Female service members could be able to start training as Army paratroopers and Navy commandos in the next few years.

5. SYRIA'S KURDS FURTHER COMPLICATE CIVIL WAR

By pursuing a path of autonomy, the nation's Kurdish minority could add another layer of ethnic tensions to the fighting.

6. WHY KRAFT'S PACKAGED TURKEY SLICES LOOK LIKE LEFTOVERS

It's an example of food companies trying their best to make processed foods appear homemade.

7. HIGH DRAMA ON FLIGHT FROM HONG KONG

Passengers and a flight attendant jump on a screaming man and bind him hand and foot for the last six hours of a flight to the U.S.

8. WHO'S MAKING MARIJUANA ACTIVISTS UNEASY

An ex-Microsoft manager wants to build a nationwide pot empire ? a venture that could draw unwanted attention from the federal government.

9. STREISAND ADDRESSES ONE OF ISRAEL'S TOUCHIEST TOPICS

Visiting Jerusalem, the entertainer criticizes Jewish religious practices that separate men and women.

10. WHICH COUPLE NOW MOVES TO CENTER STAGE

With Kim Kardashian having given birth, the next highly anticipated celebrity baby is Prince William and Kate Middleton's. She's expecting in mid-July.

Source: http://news.yahoo.com/10-things-know-tuesday-103642113.html

whitney houston in casket photo resolute national enquirer whitney houston casket photo jk rowling qnexa kingdom of heaven national enquirer whitney houston

China pressured U.S. university to make him leave, dissident says

By Jonathan Allen

NEW YORK (Reuters) - Chen Guangcheng, the Chinese dissident who fled his home country to become a visiting scholar at New York University, accused the school on Sunday of asking him to leave because of "unrelenting pressure" from China.

NYU denied the claim, saying that it had said last year before the blind dissident arrived that his fellowship would last up to a year and end sometime this summer.

Chen sparked a diplomatic crisis between the United States and China after he fled house arrest last year and sought refuge at the U.S. Embassy in Beijing. NYU helped Chen come to the United States after he expressed fears for his family's safety if they were to remain in China.

In a statement, Chen thanked NYU for its hospitality and "good support," but accused it of giving in to the Communist Party of China.

"In fact, as early as last August and September, the Chinese Communists had already begun to apply great, unrelenting pressure on New York University, so much so that after we had been in the United States just three to four months, NYU was already starting to discuss our departure with us," he wrote.

Chen, who was born blind and taught himself law, was a campaigner for farmers and disabled citizens. He exposed forced abortions in China before he was placed under house arrest in Shandon province.

He has continued to be critical of China's human rights record since his arrival in New York in May 2012 with his wife and two children.

Jerome Cohen, an NYU law professor and friend of Chen who helped broker his departure from China, told Reuters that "we should all base accusations on facts, not speculation and conspiracy theories unsupported by facts", when asked for a response to Chen's remarks.

TV INTERVIEW

Chen said he believed the Chinese government wanted "to make me so busy trying to earn a living that I don't have time for human rights advocacy, but this is not going to happen."

NYU pointed to a PBS television interview in May 2012 with Cohen, who had said Chen would be at NYU for a year at most while he adjusted to a new country.

Chen could not be reached for comment on Sunday.

John Beckman, an NYU spokesman, described Chen's claims as "both false and contradicted by the well-established facts."

"Mr. Chen's fellowship at NYU and its conclusion have had nothing to do with the Chinese government. All fellowships come to an end," Beckman said in a statement.

NYU said Chen had received offers from two other academic institutions. Fordham University Law School in New York said on Friday it was in talks with Chen.

The second offer is from the Witherspoon Institute, based in Princeton, New Jersey, Bob Fu, the president of Texas-based Christian advocacy group ChinaAid told Reuters. Chen has not yet made a decision, said Fu, whose group has campaigned for Chen.

The Witherspoon Institute is a think-tank that opposes same-sex marriage and abortion.

Beckman said NYU had started talking with the Chens about changes in living arrangements months ago. The school has provided them services that include housing, food, insurance and healthcare, English lessons and family support, he said.

NYU has been building a campus in Shanghai, and received final approval from China's education ministry to begin construction and student recruitment last autumn.

(Additional reporting by Ian Simpson in New York and Sui-Lee Wee in Beijing; Editing by Eric Walsh and Clarence Fernandez)

Source: http://news.yahoo.com/china-pressured-nyu-him-leave-dissident-says-014313332.html

chris brown and rihanna nightline brady quinn brady quinn bloom box obama sweet home chicago accenture match play